The Roche Group is to coordinate a new project under the Innovative Medicines Initiative (IMI) under which 1,500 induced pluripotent stem (iPS) cell lines will be generated and characterised for use in the study of disease. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Research & University News
